摘要
Abstract
Objective To quickly evaluate the effectiveness,safety and economy of Guanfacine Hydrochloride Extended Release Tablets(hereinafter referred to as guanfacine)in the treatment of attention deficit hyperactivity disorder(ADHD)in children.Methods Systematic reviews/Meta-analyses,HTA reports and pharmacoeconomic studies with guanfacine as the intervention drug were searched from the CNKI,WanFang,VIP,PubMed,ScienceDirect,EBSCO,Web of Science,Springer,SciFinder and health technology assessment(HTA)-related websites.The quality of HTA reports was evaluated by the HTA Checklist,the quality of systematic reviews/Meta-analyses was evaluated by a measurement tool to assess systematic reviews(AMSTAR),and the quality of pharmacoeconomic studies was evaluated by the consolidated health economic evaluation reporting standards(CHEERS).Results One HTA report(with high quality),six Meta-analyses/network Meta-analyses(all with high quality)and four pharmacoeconomic studies(unable to evaluate quality)were included.For effectiveness,guanfacine monotherapy and combination therapy with other drugs can more effectively improve the Clinical Global Impression(CGI)Scale and ADHD Rating Scale Ⅳscores in children than placebo(P<0.05).For safety,guanfacine had higher incidence of drug withdrawal due to adverse reaction and sleep disorders and more obvious decrease of body mass than placebo(P<0.05),and it had lower incidence of appetite decrease than atomoxetine(P<0.05).For economy,guanfacine had a more obvious cost-effectiveness advantage than atomoxetine.Conclusion Guanfacine is effective and safe in the treatment of ADHD,and is economical among similar drugs,which needs further verification by domestic economic studies.关键词
盐酸胍法辛缓释片/有效性/安全性/经济性/卫生技术评估Key words
Guanfacine Hydrochloride Extended Release Tablets/effectiveness/safety/economy/health technology assessment分类
医药卫生
